Legend Biotech
Legend Biotech is a global biotechnology company headquartered in Somerset, New Jersey, specializing in developing and commercializing novel therapies, including CAR-T cell therapies for cancer treatment.
Company Overview
Legend Biotech is a global, commercial-stage biotechnology company headquartered in Somerset, New Jersey. The company focuses on developing, manufacturing, and commercializing novel therapies aimed at improving the lives of patients worldwide. Legend Biotech's operations extend to multiple international locations, including facilities in Piscataway, New Jersey; Nanjing, China; Dublin, Ireland; and Ghent, Belgium. With a team of over 1,000 employees, the company is committed to advancing cutting-edge cell therapies and has built a robust framework for innovative research and development.
CARVYKTI® (Ciltacabtagene Autoleucel)
Legend Biotech, in collaboration with Janssen Biotech, Inc., has developed CARVYKTI® (ciltacabtagene autoleucel). This therapy is the first and only BCMA-targeted CAR-T cell therapy approved by the FDA for second-line treatment of multiple myeloma. Additionally, it has received approval from the European Commission. CARVYKTI® is a significant achievement in the company's portfolio, designed to provide critical care for patients with relapsed and refractory multiple myeloma.
Research and Development
Legend Biotech boasts a comprehensive R&D pipeline that includes a variety of investigational agents and innovative technologies in personalized medicine. Their technology platforms feature autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, natural killer (NK) cells, and gamma-delta (γδ) T cells. The company is also exploring non-gene-editing universal CAR-T technology. Through strategic collaborations and a commitment to cutting-edge research, Legend Biotech continues to advance its cell therapy platforms.
Strategic Collaborations
Legend Biotech actively engages in strategic collaborations to drive the development and commercialization of its therapies. Notably, the company's partnership with Janssen Biotech, Inc. has been pivotal in the progress of CARVYKTI® (ciltacabtagene autoleucel). These collaborations help Legend Biotech harness external expertise and resources, facilitating faster and more effective advancement of their therapeutic offerings.
Environmental, Social, and Governance (ESG) Initiatives
Legend Biotech has a strong focus on sustainability, as evidenced by their inaugural Environmental, Social, and Governance (ESG) report published in March 2024. The company aims to prioritize efficiency and integrity through robust governance and environmental, health, and safety management. Legend Biotech is dedicated to creating a positive impact on society while advancing their mission in the biotechnology sector. Their commitment to ESG principles ensures that they operate responsibly and sustainably.